Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGAT1 | O75907 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | CA12 | O43570 | 1/20 | 0.32 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.32 |
| ▸ | CA1 | P00915 | 1/20 | 0.31 |
| ▸ | CA2 | P00918 | 1/20 | 0.31 |
| ▸ | CA7 | P43166 | 1/20 | 0.31 |
| ▸ | NOS1 | P29475 | 2/20 | 0.31 |
| ▸ | GAA | P10253 | 2/20 | 0.31 |
| ▸ | NOS3 | P29474 | 1/20 | 0.31 |
| ▸ | NOS2 | P35228 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6822603 | 0.95 | DGAT1 (0.36) | DGAT1KMT2ALMNACA12CA14 | |
| SCHEMBL9250430 | 0.80 | ELANE (0.40) | KMT2ALMNACA12CA14CA1 | |
| SCHEMBL353409 | 0.78 | MAPT (0.37) | LMNAGAA | |
| SCHEMBL11093713 | 0.78 | LMNA (0.31) | KMT2ALMNAGAA | |
| SCHEMBL17243717 | 0.77 | HTT (0.34) | DGAT1KMT2ALMNACA12CA14 | |
| SCHEMBL1141948 | 0.77 | CA12 (0.35) | DGAT1KMT2ALMNACA12CA14 | |
| SCHEMBL19438184 | 0.77 | BTK (0.36) | KMT2AGAAMEN1 | |
| SCHEMBL2440492 | 0.75 | FAAH (0.38) | DGAT1KMT2ALMNACA12CA14 | |
| SCHEMBL3827638 | 0.75 | LMNA (0.37) | DGAT1KMT2ALMNACA12CA14 | |
| SCHEMBL5409743 | 0.75 | NOS1 (0.36) | DGAT1KMT2ALMNACA12CA14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7560550-B2 | Method for the production of OH protected[4-(2.6-diamino-9H-purine-9-yl)-1.3-dioxolane-2-yl]methanol derivatives | RFS PHARMA, LLC (US) | 2009-07-14 | — | — | US | claimed |
| US-7763740-B2 | Method for the production of mumbaistatin derivatives | SANOFI-AVENTIS (FR) | 2010-07-27 | — | — | US | disclosed |
| US-7560550-B2 | Method for the production of OH protected[4-(2.6-diamino-9H-purine-9-yl)-1.3-dioxolane-2-yl]methanol derivatives | RFS PHARMA, LLC (US) | 2009-07-14 | — | — | US | disclosed |
| US-20090156836-A1 | METHOD FOR THE PRODUCTION OF MUMBAISTATIN DERIVATIVES | SANOFI-AVENTIS (FR) | 2009-06-18 | — | — | US | disclosed |
| EP-2010474-A1 | METHOD FOR THE PRODUCTION OF MUMBAISTATIN DERIVATIVES | Sanofi-Aventis (FR) | 2009-01-07 | — | — | EP | disclosed |
| WO-2007121822-A1 | METHOD FOR THE PRODUCTION OF MUMBAISTATIN DERIVATIVES | SANOFI-AVENTIS (DE) | 2007-11-01 | — | — | WO | disclosed |
| US-20060211855-A1 | Method for the production of oh protected{4-(2.6-diamino-9h-purine-9-yl)-1.3-dioxolane-2-yl] methanol derivatives | WACKER CHEMIE AG (DE) | 2006-09-21 | — | — | US | disclosed |
| EP-1212285-B1 | METHOD OF PRODUCING 2-HYDROXYCARBOXYLIC ACID ESTERS | ABBOTT GMBH & CO KG (DE) | 2005-02-02 | — | — | EP | disclosed |
| US-6646152-B1 | Decyclization of glycidyl ester using organoaluminum reagent; no side reactions | ABBOTT GMBH & CO. KG (DE) | 2003-11-11 | — | — | US | disclosed |
| EP-1212285-A1 | METHOD OF PRODUCING 2-HYDROXYCARBOXYLIC ACID ESTERS | BASF AKTIENGESELLSCHAFT (DE) | 2002-06-12 | — | — | EP | disclosed |
| WO-2001019774-A1 | METHOD OF PRODUCING 2-HYDROXYCARBOXYLIC ACID ESTERS | BASF AKTIENGESELLSCHAFT (DE) | 2001-03-22 | — | — | WO | disclosed |
| US-5338639-A | Heat and moisture resistant stabilizers which give sharp, deeply colored images when developed | BASF AKTIENGESELLSCHAFT (DE) | 1994-08-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090156836-A1 | METHOD FOR THE PRODUCTION OF MUMBAISTATIN DERIVATIVES | MMAB, MLYCD, HMBS | DGAT1 1554/4885KMT2A 924/4885LMNA 2612/4885 |
| US-20060211855-A1 | Method for the production of oh protected{4-(2.6-diamino-9h-purine-9-yl)-1.3-dioxolane-2-yl] methanol derivatives | FUT6, FUT5, ST6GAL1 | DGAT1 2384/4885KMT2A 1922/4885LMNA 488/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.